Dose-escalation study of infliximab or methotrexate based on the disease activity in patients with rheumatoid arthritis treated with infliximab

Dose-escalation study of infliximab or methotrexate based on the disease activity in patients with rheumatoid arthritis treated with infliximab - Study of dose-escalation therapy in IFX-treated RA

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008281

Enrollment

Registered

2012-06-28

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Dose-escalation of MTX or IFX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients inadequately responded to MTX therapy

Exclusion criteria

Exclusion criteria: Patients with remmission and low disease acitivuty. Patients contraindicated or unsuitable to IFX administration, such as active infection.

Design outcomes

Primary

Measure	Time frame
Improvement rate of disease acitivity based on DAS28 and SDAI at 54 week	—

Countries

Japan

Contacts

Public ContactNaoto Tamura

Juntendo University Hospital Internal Medicine and Rheumatology

tnaoto@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026